Advancing technology development, commercialization, and ecosystem creation
[by Ji, Yong Jun] The OSONG Medical Innovation Foundation (KBIOHealth) announced on May 26 the signing of a memorandum of understanding (MOU) with Kolmar Holdings, aimed at fostering the development of cosmetics, pharmaceuticals, and health functional foods, as well as enhancing global market competitiveness.
The agreement was promoted to strategically integrate the research infrastructure of public institutions with the industrial capabilities of private enterprises, with the objective of advancing technological development and commercialization in the bio온라인바카라 sector, while also laying the groundwork for a sustainable cooperative ecosystem.
The primary areas of cooperation outlined in the agreement include joint research and development of anticancer drugs and autoimmune diseases, support for non-clinical evaluation and collaborative research for cosmetics and 온라인바카라 functional foods, production and analytical evaluation of biopharmaceutical samples for use in clinical trials, among other initiatives.
“This agreement represents an important turning point for the development of biotechnology, 온라인바카라, and beauty products through public-private collaboration and for strengthening global market competitiveness,” expressed Lee Myung-su, CEO of KBIO온라인바카라. “We will continue to make every effort to reinforce the global competitiveness of Korea’s biotechnology, 온라인바카라, and beauty industries through sustainable cooperation initiatives.”
“This agreement will enable us to integrate the strengths of both parties to expedite the development of globally competitive cosmetics, pharmaceuticals, and 온라인바카라 functional foods,” said Yoon Sang-hyun, CEO of Kolmar Holdings.
Since its establishment in 2010, KBIO온라인바카라 has built the nation’s leading infrastructure for the bio온라인바카라 industry and has provided comprehensive support services throughout the entire commercialization process. This includes research assistance for novel drugs and medical devices, non-clinical trials, samples and finished product manufacturing, and regulatory science services. Celebrating its 15th anniversary this year, KBIO온라인바카라 is at the forefront of leading the ‘Bio 4.0’ era, actively expanding both domestic and international partnerships to drive the global advancement of Korea’s bio온라인바카라 sector.